Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Benzinga's M&A Chatter for Tuesday June 21, 2016

TSLA, OSIS, TEVA, PHG

The following are the M&A deals, rumors and chatter circulating on Wall Street for Tuesday June 21, 2016:

Tesla Makes Offer to Acquire SolarCity

The Offer:
Tesla (NASDAQ: TSLA) announced Tuesday, an offer to acquire all the outstanding shares of SolarCity (NASDAQ: SCTY) common stock for $26.50 to $28.50 per share. Tesla is proposing an exchange ratio of 0.122x to 0.131x shares of Tesla common stock for each share of SolarCity common stock.

Tesla's Board of Directors made the offer in a letter to SolarCity CEO Lyndon Rive.

Solar City closed Tuesday at $21.19 and traded as high as $27.23 after hours. There was activity in the October $30 call just ahead of the close. Tesla shares fell below $190 after closing at $219.61.

AS&E to Be Acquired by OSI Systems for $37/Share in Cash

The Deal:
American Science and Engineering, Inc. (NASDAQ: ASEI) announced Tuesday that it has agreed to be acquired by OSI Systems, Inc. (NASDAQ: OSIS) for $37.00 per share in cash transaction, for a total transaction value of approximately $269 million. The transaction is expected to close by the end of 2016.

ASEI closed Tuesday at $36.88 up 14.04%.

Impax Agrees to Buy Generic Products for $586M

The Deal:
Impax Laboratories, Inc. (NASDAQ: IPXL) announced Tuesday, that it has signed agreements with Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and affiliates of Allergan plc (NYSE: AGN) to acquire a broad portfolio of generic products including solid oral, inhalable, injectable and topical dosage forms and the return to Impax of its rights to its pending ANDA for the generic equivalent to Concerta for $586 million.

Closing is expected to occur coincidently with the closing of the Teva-Allergan Generics transaction.

Impax closed at $28.31 on Tuesday, down 11.45%.

Philips Acqures PathXL

The Deal:
Royal Philips (NYSE: PHG) today announced Tuesday, that it has acquired PathXL. Financial details of the transaction were not disclosed.

PathXL is a Northern Ireland-based leader in digital pathology image analysis, workflow software and educational tools.

Philips closed at $26.15 on Tuesday up 1.75%.



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today